Cite
HARVARD Citation
Shinozaki, E. et al. (n.d.). 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). European journal of cancer. pp. S383-S384. [Online].